Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2003) 5 S37

Wake Forest University School of Medicine, Winston-Salem, NC, USA.


During the past decade, few topics in medicine have been more controversial or clinically relevant than the effects of hormone replacement therapy (HRT) on risk for cardiovascular disease (CVD) in postmenopausal women. Based on extensive observational, animal model, and in vitro studies, many clinicians and patients were convinced that HRT lowered risk for CVD, a perception that helped make HRT use one of the most well-established treatment paradigms in American medicine. However, recent unexpected negative results from randomized clinical trials, including the Women's Health Initiative announced in July, have completely revised this view, transforming our understanding of the effect of HRT on CVD risk from one of presumed benefit to one of proven harm. This surprising turn of events has made it clear that the effects of HRT on vascular health are far more complex than initially assumed and urgently in need of additional study. Understanding how it is that estrogen, which has such favorable effects on intermediate pathways such as lipid metabolism and endothelial function, could nonetheless increase risk for CHD events would undoubtedly shed new light on the pathogenesis of atherosclerosis and provide fundamentally important additional information concerning estrogen biology. These issues will be discussed in detail.

Volume 5

22nd Joint Meeting of the British Endocrine Societies

British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

HRT and the heart (<1 min ago)